Ovid Therapeutics Inc. (OVID) Stock

Ovid Therapeutics Inc. (OVID) is a Healthcare stock trading at $2.29 (as of 2026-06-18), with a market capitalization of $509.53M and a trailing P/E of -21.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing drug candidates for neurological disorders. Its pipeline includes candidates such as OV101 for fragile X syndrome and OV329 and OV350 for seizure-related conditions, along with other programs including gene therapy and small-molecule approaches, with clinical development conducted in the U.S.

Valuation — source: SEC EDGAR (first-party)
Price	$2.29
Market Cap	$509.53M
P/E Ratio	-21.1
EV / EBITDA	-8.7
Price / Book	2.57
Price / Sales	71.54
DCF Value (model)	$-4.83
DCF Upside vs Price	-310.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$7.25M
Net Margin	-240.1%
Return on Equity	-12.2%
Current Ratio	10.17
Revenue Growth (YoY)	1181.3%
FCF Growth (YoY)	-31.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	5.60 (safe)

Valuation vs Sector & Industry
Stock P/E	-21.1
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-200.9%
vs Industry	-223.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RA CAPITAL MANAGEMENT, L.P. ($23.79M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Margaret Alexander
Employees	23
Country	US
IPO Date	2017-05-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.